Clinical significance of alterations of chromosome 8 in high-grade, advanced, nonmetastatic prostate carcinoma

Journal of the National Cancer Institute

Volumn 91, Issue 18, 1999, Pages 1574-1580

  Sato, Kazunari ^a   Qian, Junqi ^a   Slezak, Jeffrey M ^a   Lieber, Michael M ^a   Bostwick, David G ^a   Bergstralh, Erik J ^a   Jenkins, Robert B ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED CANCER; ARTICLE; CENTROMERE; CHROMOSOME 8; CHROMOSOME ABERRATION; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN TISSUE; ONCOGENE C MYC; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CARCINOMA; RISK FACTOR; TUMOR GROWTH;

EID: 0033568130     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/91.18.1574     Document Type: Article

References (38)

1. Bova GS, Carter BS, Bussemakers MJ, Emi M, Fujiwara Y, Kyprianou N, et al. Homozygous deletion and frequent allelic loss of chromosome 8p22 loci in human prostate cancer. Cancer Res 1993;53:3869-73.
2. Macoska JA, Trybus TM, Benson PD, Sakr WA, Grignon DJ, Wojno KD, et al. Evidence for three tumor suppressor gene loci on chromosome 8p in human prostate cancer. Cancer Res 1995;55:5390-5.
3. Kagan J, Stein J, Banaian RJ, Joe YS, Pisters LL, Glassman AB, et al. Homozygous deletions at 8p22 and 8p21 in prostate cancer implicate these regions as the sites for candidate tumor suppressor genes. Oncogene 1995;11: 2121-6.
4. Crundwell MC, Chughtai S, Knowles M, Takle L, Luscombe M, Neoptolemos JP, et al. Allelic loss on chromosomes 8p, 22q and 18q (DCC) in human prostate cancer, Int J Cancer 1996; 69:295-300.
5. Emmert-Buck MR, Vocke CD, Pozzatti RO, Duray PH, Jennings SB, Florence CD, et al. Allelic loss on chromosome 8p 12-21 in micro-dissected prostatic intraepithelial neoplasia. Cancer Res 1995;55:2959-62.
6. Cher ML, MacGrogan D, Bookstein R, Brown JA, Jenkins RB, Jensen RH. Comparative genomic hybridization, allelic imbalance, and fluorescence in situ hybridization on chromosome 8 in prostate cancer. Genes Chromosomes Cancer 1994;11:153-62.
7. Visakorpi T, Kallioniemi AH, Syvanen AC, Hyytinen ER, Karhu R, Tammela T, et al. Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization. Cancer Res 1995;55:342-7.
8. Van Den Berg C, Guan XY, Von Hoff D, Jenkins R, Bittner M, Griffin C, et al. DNA sequence amplification in human prostate cancer identified by chromosome microdissection: potential prognostic implications. Clin Cancer Res 1995;1:11-8.
9. Nupponen NN, Kakkola L, Koivisto P, Visakorpi. Genetic alterations in hormonerefractory recurrent prostate carcinomas. Am J Pathol 1998;153:141-8.
10. Depinho RA, Schreiber-Agus N, Alt FW. myc family oncogenes in the development of normal and neoplastic cells. Adv Cancer Res 1991;57:1-46.
11. Jenkins RB, Qian J, Lieber MM, Bostwick DG. Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. Cancer Res 1997;57: 524-31.
12. Qian J, Bostwick DG, Takahashi S, Borell TJ, Herath JF, Lieber MM, et al. Chromosomal anomalies in prostatic intraepithelial neoplasia and carcinoma detected by fluorescence in situ hybridization. Cancer Res 1995;55: 5408-14.
13. Ried T. Interphase cytogenetics and its role in molecular diagnostics of solid tumors. Am J Pathol 1998;152:325-7.
14. Pauletti G, Godolphin W, Press MF, Slamon DJ. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene 1996;13:63-72.
15. Macoska JA, Trybus TM, Sakr WA, Wolf MC, Benson PD, Powell IJ, et al. Fluorescence in situ hybridization analysis of 8p allelic loss and chromosome 8 instability in human prostate cancer. Cancer Res 1994;54:3824-30.
16. Deubler DA, Williams BJ, Zhu XL, Steele MR, Rohr LR, Jensen JC, et al. Allelic loss detected on chromosomes 8, 10, and 17 by fluorescence in situ hybridization using single-copy P1 probes on isolated nuclei from paraffin-embedded prostate tumors. Am J Pathol 1997;150:841-50.
17. Jenkins RB, Qian J, Lee HK, Huang H, Hirasawa K, Bostwick DG, et al. A molecular cytogenetic analysis of 7q31 in prostate cancer. Cancer Res 1998;58:759-66.
18. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988;319:525-32.
19. Orntoft TF, Wolf H. Molecular alterations in bladder cancer [editorial]. Urol Res 1998;26: 223-33.
20. 0 prostate cancer. Genes Chromosomes Cancer 1998;21: 131-43.
21. Schroder FH, Hermanek P, Denis L, Fair WR, Gospodarowicz MK, Pavone-Macaluso M. The TNM classification of prostate cancer. Prostate Suppl 1992;4:129-38.
22. Zincke H, Oesterling JE, Blute ML, Bergstralh EJ, Myers RP, Barrett DM. Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol 1994;152:1850-7.
23. Bova GS, Isaacs WB. Review of allelic loss and gain in prostate cancer. World J Urol 1996; 14:338-46.
24. Prasad MA, Trybus TM, Wojno KJ, Macoska JA. Homozygous and frequent deletion of proximal 8p sequences in human prostate cancers: identification of a potential tumor suppressor gene site. Genes Chromosomes Cancer 1998;23:255-62.
25. Buttyan R, Sawczuk IS, Benson MC, Siegal JD, Olsson CA. Enhanced expression of the c-myc protooncogene in high-grade human prostate cancers. Prostate 1987;11:327-37.
26. Fleming WH, Hamel A, MacDonald R, Ramsey E, Pettigrew NM, Johnston B, et al. Expression of the c-myc protooncogene in human prostatic carcinoma and benign prostalic hyperplasia. Cancer Res 1986;46:1535-8.
27. Steiner P, Philipp A, Lukas J, Godden-Kent D, Pagano M, Mittnacht S, et al. Identification of a Myc-dependent step during the formation of active G1 cyclin-cdk 7complexes. EMBO J 1995;14:4814-26.
28. Bouchard C, Staller P, Eilers M. Control of cell proliferation by Myc. Trends Cell Biol 1998; 8:202-6.
29. kip1 in prostatic adenocarcinoma. Mod Pathol 1998;11:324-8.
30. Kip1 levels with recurrence and survival in patients with stage C prostate carcinoma. J Natl Cancer Inst 1998;90:916-20.
31. KIp1 gene expression in benign prostatic hyperplasia and prostatic carcinoma. J Natl Cancer Inst 1998;90:1284-91.
32. Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma. Cancer Res 1998;58:542-8.
33. Steiner MS, Anthony CT, Lu Y, Holt JT. Antisense c-myc retroviral vector suppresses established human prostate cancer. Hum Gene Ther 1998;:747-55.
34. Dong JT, Lamb PW, Rinker-Scnaeffer CW, Vukanovic J, Ichikawa T, Isaacs JT, et al. KAI1 a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. Science 1995;68:884-6.
35. Bostwick DG, Myers RP, Oesterling JE. Staging of prostate cancer. Semin Surg Oncol 1994; 10:60-72.
36. Takahushi S, Qian J, Brown JA, Alcaraz A, Bostwick DG, Lieber MM, et al. Potential markers of prostate cancer aggressiveness detected by fluorescence in situ hybridization in needle biopsies. Cancer Res 1994;54:3574-9.
37. Persons DL, Gibney DJ, Katzmann JA, Lieber MM, Farrow GM, Jenkins RB. Use of fluorescent in situ hybridization for deoxyribonucleic acid ploidy analysis of prostatic adenocarcinoma. J Urol 1993;150:120-5.
38. Reiter RE, Gu Z, Watanabe T, Thomas G, Szigeti K, Davis E, et al. Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci USA 1998;95:1735-40.